Osimertinib in locally advanced or metastatic non‑small cell lung cancer therapy

05/2019

MUDr. Libor Havel

Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

Epidermal growth factor receptor (EGFR) mutations are found in 10-14 % lung cancer patients in Central Europe. Therapeutic standard for these patients are EGFR-tyrosinkinase inhibitors (TKI). Screening for these mutations became a diagnostic standard in adenocarcinoma histology. Majority of these mutations are sensitizing mutations (Del 19, exon 21 point mutations). Main resistance mechanism after prior EGFR tyrosinkinase inhibitors therapy is exon 20 mutation T790M. Osimertinib is third generation EGFR tyrosinkinase inhibitors that selectively inhibits both EGFR-TKI sensitizing and EGFR T790M resistance mutations.

Key words

epidermal growth factor, non-small cell lung cancer, tyrosinkinase inhibitors, osimertinib